Publications by authors named "William D Renton"
Introduction: We aim to report on the feasibility of establishment of the first paediatric cohort as part of the longitudinal database of the Australian Lupus Registry and Biobank (ALRB) and to describe the enrolment data with a focus on clinical characteristics, serological data, treatment strategies and patient/parent-reported outcome measures.
Methods: All patients under the age of 18 years with a diagnosis of systemic lupus erythematosus (SLE) attending the paediatric rheumatology service of a single, tertiary hospital were identified. Patients were enrolled in the ALRB if they met ≥4/11 of the American College of Rheumatology (ACR) 1997 SLE classification criteria or the Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria.
Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. Methotrexate has broad immunomodulatory properties and is the most commonly used disease-modifying antirheumatic drug (DMARD). This is an update of a 2001 Cochrane review.
View Article and Find Full Text PDFReassuring short-term effect of corticosteroids for Kawasaki disease.
J Paediatr Child Health
January 2023
Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.
Cochrane Database Syst Rev
October 2022
Article Synopsis
- Uveitis is a serious eye condition often associated with juvenile idiopathic arthritis (JIA), and its treatment currently varies widely among physicians due to a lack of standard protocols.
- This study aimed to assess the effectiveness and safety of tumor necrosis factor (TNF) inhibitors in children aged 2-18 with JIA-related uveitis by reviewing randomized controlled trials.
- Three studies involving 134 participants were analyzed, revealing that TNF inhibitors may not significantly improve treatment outcomes compared to placebo, indicating a need for further research in this area.
Background: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic inflammatory disease in childhood. Optimal management requires clinicians to be up to date with the rapidly evolving evidence base. 'Living' evidence-based clinical practice guidelines, which integrate new evidence as soon as it is available, are a novel method to enhance the translation of research into practice.
View Article and Find Full Text PDFBackground: Biologic medications have dramatically enhanced the treatment of many chronic paediatric inflammatory conditions. Their high cost is a factor that prohibits their broader use. Cheaper generic versions, or biosimilars, are increasingly being used.
View Article and Find Full Text PDFArticle Synopsis
- Disabling pansclerotic morphea of childhood (DPMC) is a rare and aggressive form of juvenile localized scleroderma affecting primarily children under 14, leading to severe complications such as joint contractures and skin ulceration.
- Over a 29-month treatment period, a 5-year-old boy with refractory DPMC showed some improvement with prednisolone and mycophenolate mofetil (MMF), while other therapies like biologics and tyrosine kinase inhibitors proved ineffective, ultimately leading to a referral for a stem cell transplant.
- A literature review found that common treatments include methotrexate and corticosteroids, with MMF having anecdotal success; however, many patients end up needing intensive, multi-modal immun
Background: Telemedicine has emerged as an alternative mode of health care delivery over the last decade. To date, there is very limited published information in the field of telehealth and paediatric nephrology. The aim of this study was to review our experience with paediatric telenephrology in Queensland, Australia.
View Article and Find Full Text PDF